Sandeep Lal V, Arora S, Dabas R, et al. - Researchers undertook this prospective single center observational study to determine whether single injection of Omalizumab affords an efficacious treatment choice for patients suffering from Chronic Spontaneous Urticaria (CSU). Experts administered single dose of injection Omalizumab 300mg to 30 patients of CSU on double the dose of tablet Fexofenadine 180mg with Urticaria Activity Score (UAS 7) more than 15. Up to 6 months, their response was evaluated employing UAS‐7. In early responders, single injection of Omalizumab followed by antihistamines resulted in prolonged symptom free intervals, which avoided over treatment with Omalizumab as well as was cost saving in the long‐term treatment of these cases. In CSU management, the use of an individualized, cost‐effective approach is possible, with the careful monitoring of UAS7 scores. This work may ascertain a novel standard of care with respect to limiting the doses of a biologic.